Sierra Oncology (Sierra Oncology) Interest Expense : $0.00 Mil (TTM As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sierra Oncology's interest expense for the three months ended in Mar. 2022 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2022 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sierra Oncology's Operating Income for the three months ended in Mar. 2022 was $ -27.88 Mil. Sierra Oncology's Interest Expense for the three months ended in Mar. 2022 was $ 0.00 Mil. GuruFocus does not calculate Sierra Oncology's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sierra Oncology Interest Expense Historical Data

The historical data trend for Sierra Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology Interest Expense Chart

Sierra Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Interest Expense

Get a 7-Day Free Trial

Sierra Oncology Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sierra Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Sierra Oncology (NAS:SRRA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sierra Oncology's Interest Expense for the three months ended in Mar. 2022 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2022 was $-27.88 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2022 was $5.30 Mil.

Sierra Oncology's Interest Coverage for the quarter that ended in Mar. 2022 is calculated as

GuruFocus does not calculate Sierra Oncology's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Sierra Oncology Inc has enough cash to cover all of its debt. Its financial situation is stable.

Sierra Oncology (Sierra Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1820 Gateway Drive, Suite 110, San Mateo, USA, 94404

Website

https://www.sierraoncology.com

Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.

Executives

Vivo Opportunity Fund Holdings, L.p.	director, 10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner	officer: Chief Reg & Tech Ops Officer	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson	officer: General Counsel	C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson	director, 10 percent owner	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal	director, 10 percent owner	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair	director	C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459